Physician profile
Robert Miller
NPI 1205845153
$2,195.37
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,089 · 2021: $46.84 · 2022: $59.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $1,650.00 | 2019 | |
| Mdd US Operations, LLC | $83.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $69.28 | 2019 | |
| Avanir Pharmaceuticals, INC. | $69.13 | 2019 | |
| Sk Life Science, INC. | $57.11 | 2021-2022 | |
| Edw Pharma, INC. | $53.85 | 2019 | |
| Biogen, INC. | $52.38 | 2019-2022 | |
| Genzyme Corporation | $50.20 | 2019 | |
| Csl Behring | $38.65 | 2019 | |
| Akcea Therapeutics, INC. | $29.98 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.74 | 2021 | |
| Shire North American Group INC | $17.75 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.